Benzene and Acute Myeloid Leukemia: Clinical Evidence Review of Causation

From General Health Information to Occupational Risk Analysis

This domain has historically provided accessible health and science information derived from structured public data sources such as ClinicalTrials.gov, PubMed, and FDA databases. This foundation supports evidence-based reviews of clinical trials, drug safety, and disease overviews with clarity and neutrality. Building on that legacy, we now focus on occupational exposure concerns, specifically the link between benzene—a widely used industrial solvent—and acute myeloid leukemia (AML). This transition leverages the same rigorous data synthesis approach, now applied to occupational epidemiology rather than broad therapeutic reviews, to address how chronic benzene exposure in manufacturing and industrial settings elevates leukemia risk.

Benzene as a Recognized Carcinogen: Evidence for AML Causation

Benzene is a recognized myelotoxin and carcinogen, with chronic exposure linked to an increased risk of acute myeloid leukemia (AML) and other hematological neoplasms (https://pubmed.ncbi.nlm.nih.gov/34069279/). The clinical presentation of AML typically includes symptoms related to bone marrow failure, such as fatigue, infection, and bleeding, along with laboratory findings of cytopenias and circulating blasts. Diagnosis requires bone marrow examination demonstrating at least 20% myeloid blasts. Benzene exposure can initiate AML through multiple mechanistic pathways, including genotoxic effects, oxidative stress and inflammation, and immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). These mechanisms are not fully explanatory, as genetic alterations alone are insufficient to account for all hematologic malignancies, suggesting epigenetic factors also play a role (https://pubmed.ncbi.nlm.nih.gov/34069279/).

Quantitative Risk Assessment and Exposure-Response Relationships

Occupational exposure to benzene at levels of 10 ppm or more has been associated with an increased risk of AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). The mode of action for AML development involves multiple key events, including hematotoxicity and genetic toxicity observable in peripheral blood of exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013/). Preventing these early events could prevent the apical adverse outcomes of myelodysplastic syndromes (MDS) and AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). Previous studies have established a causal relationship between occupational benzene exposure and AML (https://pubmed.ncbi.nlm.nih.gov/38727681/). However, mixed results exist for associations with other myeloid and lymphoid malignancies (https://pubmed.ncbi.nlm.nih.gov/38727681/). A Swiss National Cohort study examined mortality from lymphohaematopoietic cancers using a quantitative benzene job-exposure matrix applied to census-reported occupations (https://pubmed.ncbi.nlm.nih.gov/38727681/). The exposure-response relationship between benzene and AML has been estimated by combining epidemiologic, human biomarker, and animal data (https://pubmed.ncbi.nlm.nih.gov/34906966/). A linear meta-regression model best predicted AML risks when integrating six human AML studies, three human leukemia studies, ten human biomarker studies, and four experimental animal studies (https://pubmed.ncbi.nlm.nih.gov/34906966/). This approach addresses sparse data across the exposure range, improving risk assessment (https://pubmed.ncbi.nlm.nih.gov/34906966/). Additionally, a meta-analysis of childhood cancer studies found an increased risk of AML associated with benzene exposure (odds ratio 1.22, 95% CI 1.02-1.46) based on four studies with low heterogeneity (https://pubmed.ncbi.nlm.nih.gov/41485753/). This analysis also reported elevated risks for acute lymphoblastic leukemia with PM2.5 exposure and for all childhood cancers with benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753/).

Risk Communication and Clinical Implications

Regarding risk communication, the adequacy of warnings about benzene and AML is critical. Given the established causal relationship and the availability of quantitative exposure-response models, warnings should clearly convey that occupational exposure at levels of 10 ppm or more increases AML risk (https://pubmed.ncbi.nlm.nih.gov/33429013/). For affected patients, causation considerations include the latency period between exposure and disease onset, which can span years to decades, and the need to document exposure history, including job roles and duration. The timeline between exposure and documented harm is supported by evidence of hematotoxicity and genetic toxicity as early key events that precede AML development (https://pubmed.ncbi.nlm.nih.gov/33429013/). These early biomarkers can be observed in peripheral blood, providing a basis for monitoring exposed populations (https://pubmed.ncbi.nlm.nih.gov/33429013/). Overall, the evidence supports a causal link between benzene exposure and AML, with mechanistic pathways involving genotoxicity, oxidative stress, and immunosuppression, and with quantitative risk models available to inform both clinical and regulatory decisions.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the evidence linking benzene exposure to acute myeloid leukemia?

Benzene is a recognized myelotoxin and carcinogen. Chronic exposure, especially at occupational levels of 10 ppm or more, has been causally linked to AML through multiple studies. Mechanistic pathways include genotoxicity, oxidative stress, and immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). Quantitative exposure-response models combining human and animal data further support this association (https://pubmed.ncbi.nlm.nih.gov/34906966/).

What are the early signs of benzene-induced AML and how is it diagnosed?

Early signs include symptoms of bone marrow failure such as fatigue, infection, and bleeding, along with cytopenias and circulating blasts in blood tests. Diagnosis requires bone marrow examination showing at least 20% myeloid blasts. Hematotoxicity and genetic toxicity in peripheral blood are early key events that can precede AML (https://pubmed.ncbi.nlm.nih.gov/33429013/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Benzene exposure and a confirmed Acute Myeloid Leukemia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.